Newsroom: News
Bracelet aids early detection of Covid-19
Zurich – The MedTech firm Ava from Greater Zurich has developed a bracelet that monitors female fertility by determining fertile days. However, the same device can also be used for the early detection of coronavirus infections, as a study conducted in Liechtenstein has now shown.
March 23, 2021
Tech4Eva, the first Swiss start-up accelerator addressing women’s health
The EPFL Innovation Park and Groupe Mutuel are joining forces to launch Tech4Eva, the first start-up acceleration program in Switzerland addressing women’s health.
March 23, 2021
HES-SO Valais-Wallis will contribute to the world’s largest database of medical images
As part of the Horizon 2020 research program, the European project BIGPICTURE, to which the HES-SO Valais-Wallis is contributing, aims to build the world’s largest database of histopathological images.
March 16, 2021
Bern scientists develop individualized cancer models to predict therapy success
Scientists at the University of Bern and Inselspital have established organoid culture models from prostate tumor biopsies. These are small clusters of cells which can be used to test the efficacy of various drugs, helping to test which treatment will most likely benefit individual patients.
March 10, 2021
Aging brain can be reactivated
Zurich – Neuroscientists have discovered a mechanism that is partly responsible for the decrease in memory performance brought about by old age. They have also shown how nerve cell generation can be reactivated, which could benefit people with Alzheimer’s disease, for instance.
February 25, 2021
Medacta offering personalized solutions for hip replacement surgery
Castel San Pietro TI – The prosthetic specialist Medacta has developed two applications for personalized hip replacement operations. The first facilitates preoperative planning in 3D, while the second verifies exact positioning during surgery. The products have now also received clearance from the US FDA.
February 16, 2021
First patient treated with drug developed by Orpha Labs
Baar ZG – This week, the first patient was treated in Israel with a drug developed by Orpha Labs to combat the rare disorder leukocyte adhesion deficiency type II (LAD II). In particularly serious cases, a special program can be used to grant patients access to this new, highly promising drug even before it has been officially authorized.
February 9, 2021
Cartilage Repair Breakthrough is now FDA approved for US Market
Geistlich Pharma, based in Lucerne, Switzerland, has been granted Breakthrough Device Designation for Chondro-Gide® by the US Food and Drug Administration (FDA). Chondro-Gide® is a collagen membrane that is used in a one-step cartilage repair technique. The FDA’s Breakthrough Devices Program was developed in order to expedite the pathway from development through to testing of […]
February 4, 2021
B.Braun manufacturing COVID-19 vaccination sets in Lucerne
Lucerne – Together with two governmental departments in Switzerland, B. Braun Medical AG has designed COVID-19 vaccination sets for hospitals. The MedTech manufacturer has procured the individual components and has been assembling the sets at its locations in Sempach and Crissier since December 2020.
January 18, 2021
Monarch Bioimplants secures record investment at Technopark Lucerne
Monarch Bioimplants, a startup from Technopark Lucerne, is receiving 20 Million euro over the next 36 months from New York investment group GEM. The GEM Group with branches in New York, Los Angeles and Paris is making a major investment in Monarch Bioimplants. The U.S. investment group has agreed to provide Monarch Bioimplants with a […]
January 1, 2021
Virus-neutralizing UV Light to fight Infectious Disease
Technopark Lucerne – The medical and microtechnology start-up smolsys kills off viruses using ultraviolet (UV) light. The company’s innovative microtechnology components that are sealed in glass radiate 220 nanometers of UV-C light. Up until now, energy-guzzling mercury vapor lamps were required for this level of radiation power, for example to disinfect surgical instruments. The technology developed […]
January 1, 2021
Lonza manufactures coronavirus vaccine for Moderna
Lonza plans to start production of Moderna’s coronavirus vaccine in Switzerland before the end of the year. Moderna published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective. Moderna opened a subsidiary in Basel to drive forward the production of the vaccine from there.
November 17, 2020